Michael H. Davidson, Chief Executive Officer at NewAmsterdam Pharma Co N.V. (NAMS), bought 10,000 shares at $22.65 ($227K) on 2026-09-14, disclosed to the SEC on 2026-09-15.
CEO Michael Davidson purchased 10,000 shares for $226,500, marking the largest insider purchase in the company's history. This significant buyback by leadership during a period of steep stock decline suggests confidence in the company's long-term value.
The stock is down 12.94% over the last five days and 25.9% over the last 90 days, trading 46.94% below its 52-week high of $42.10. The current price of $22.34 is just 5.13% above the 52-week low of $21.25.
1) Q2 earnings on August 5, 2026, where the company reported a revenue miss of -45.41%. 2) Upcoming Investor Day updates on the obicetrapib cardiovascular outcomes strategy and commercial preparations for a potential European launch.
The stock faces significant risk due to a short interest of 13.11% of the float and a recent earnings miss where revenue fell short of estimates by 45.41%.
Something here stands out, but not much.
| Filing → |
| NAMS | BUY | 2024-08-22 | $81K | — | Filing → |
| NAMS | BUY | 2024-06-24 | $173K | — | Filing → |
| CLBS | BUY | 2020-09-10 | $100K | — | Filing → |